Bextra and Hepatic neoplasm - a phase IV clinical study of FDA data

Summary:

Hepatic neoplasm is reported as a side effect among people who take Bextra (valdecoxib), especially for people who are female, 50-59 old, also take Neurontin, and have Depression.

The phase IV clinical study analyzes which people have Hepatic neoplasm when taking Bextra. It is created by eHealthMe based on reports of 20,982 people who have side effects when taking Bextra from the FDA, and is updated regularly.

What is Bextra?

Bextra has active ingredients of valdecoxib. It is often used in pain. eHealthMe is studying from 20,994 Bextra users. Check the latest studies of Bextra.

What is Hepatic neoplasm?

Hepatic neoplasm (liver tumour) is found to be associated with 489 drugs and 519 conditions by eHealthMe. Check the latest studies of Hepatic neoplasm.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

20,982 people reported to have side effects when taking Bextra.
Among them, 13 people (0.06%) have Hepatic neoplasm.

Among these 13 people:

What is the gender of people who have Hepatic neoplasm when taking Bextra? *

female: 100 %
male: 0.0 %

What is the age of people who have Hepatic neoplasm when taking Bextra? *

What are other drugs people take besides Bextra? *

What are other side effects people have besides Hepatic neoplasm? *

White Blood Cell Count Increased: 13 people, 100.00%
Joint Injury: 13 people, 100.00%
Neck Mass (mass in neck): 13 people, 100.00%
Musculoskeletal Chest Pain (pain in chest muscle or nerve or bones): 13 people, 100.00%
Movement - Uncoordinated: 13 people, 100.00%
Mood Swings (an extreme or rapid change in mood): 13 people, 100.00%
Monocyte Count Decreased: 13 people, 100.00%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 13 people, 100.00%
Memory Loss: 13 people, 100.00%
Lymphocyte Count Decreased: 13 people, 100.00%

What are the existing conditions these people have? *

Sleep Disorder: 13 people, 100.00%
Muscle Spasms (muscle contraction): 13 people, 100.00%
Mood Swings (an extreme or rapid change in mood): 13 people, 100.00%
Depression: 13 people, 100.00%
Upper Respiratory Tract Infection: 9 people, 69.23%
Insomnia (sleeplessness): 9 people, 69.23%
Dyspnea (difficult or laboured breathing): 9 people, 69.23%
Osteoporosis (bones weak and more likely to break): 2 people, 15.38%
Metastases To Bone (cancer spreads to bone): 1 person, 7.69%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Bextra and have Hepatic neoplasm?

- Check whether Hepatic neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bextra:

Bextra (20,994 reports)

Browse all side effects of Bextra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic neoplasm:

Hepatic neoplasm (489 drugs)

Browse all the conditions that are associated with Hepatic neoplasm:

Hepatic neoplasm (519 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on valdecoxib (the active ingredients of Bextra) and Bextra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.